Neuspera’s Statement Regarding New AUA/SUFU Guideline for OAB


The American Urological Association (AUA) and Society for Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) recently published their 2024 Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder (OAB).  The guideline promotes a shared decision-making process between the patient and physician that weighs the patient’s comorbidities along with expressed values, preferences, and treatment goals in order to help them make an informed decision regarding treatment.  This completely revised guideline recognizes the difficulties and drawbacks with previous tiered therapies including behavioral interventions and medications, noting that patients may have been worn-out before having the opportunity to try more potentially attractive and effective alternatives. Options including intradetrusor botulinum toxin (botox) injection, sacral neuromodulation (SNM), and percutaneous tibial neuromodulation (PTNM), previously labeled as “third line” therapies, are now classified as “minimally invasive” therapies.


Clinicians may offer patients with OAB, in the context of shared decision making, minimally invasive therapies without requiring trials of behavioral, non-invasive, or pharmacologic management. (Expert Opinion)

The new guideline can be found here:

Neuspera Medical is encouraged by the new guideline, which will facilitate OAB patient access to their most desired and appropriate option through shared decision making with their caregiver. SNM is recognized as the “gold standard” neuromodulation therapy for OAB. The Neuspera Sacral Neuromodulation system is designed to be minimally invasive, ultra-miniaturized and to eliminate the need for an implanted battery, which we believe will be an important option for patients in their shared decision-making process.

Note: The Neuspera Sacral Neuromodulation System is currently limited to Investigational Use Only.


Steven W. Siegel, MD

Neuspera Medical CMO